Are these recent trial results a game-changer for the AstraZeneca share price?

Recent cardiovascular trial results are great news for shareholders of AstraZeneca plc (LON: AZN) but would they make me buy?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Amid all the Brexit doom and gloom, shareholders of AstraZeneca (LSE: AZN) were handed a big win recently in the form of promising new trial results. Indeed, the stock continues to make new all-time highs even as the risk of a no-deal scenario rises. In the past I have been bearish on this company. Does this news change my fundamental view on Astra? Let’s dig into the data. 

Making new highs

Shares of AstraZeneca hit new all-time highs of 7,550p on the back of positive phase 3 clinical trial data which demonstrated that diabetes drug Farxiga helped patients who had suffered heart failure. The report, delivered on Sunday, showed that Farxiga reduced mortality rates by 26% in patients with reduced ejection fraction heart failure. 

This is big news for the pharmaceutical giant, as Farxiga is already approved for the treatment of diabetes in much of the developed world. Moreover, as diabetes increases the risk of cardiovascular diseases, doctors and hospitals should be excited at the prospect of being able to kill two birds with one stone. In other Farxiga-related news, the drug was recently granted Fast Track status by the US Food and Drug Administration for the treatment of chronic kidney disease. 

Farxiga is currently forecast to net $2.5bn (£2.07bn) in sales in 2024, but that estimate now looks a bit conservative. Analysts believe that this new indication could add as much as $1bn (£0.83bn) to Astra’s valuation. That said, the company is set to lose exclusivity for the compound in 2025, which limits the potential upside for Astra. Nonetheless, it is a major (and unexpected) announcement for a company which is increasingly focusing on cancer treatments. The best discoveries are almost always random.

Stiff competition 

With all that being said, it’s important to point out that Astra’s competitors in the space haven’t been sitting on their hands either. Johnson & Johnson’s Invokana and Eli Lilly’s Jardiance (both diabetes medications with similar pharmaceutical mechanisms of action) have both also demonstrated benefits to patients with cardiovascular problems. This fact, coupled with the upcoming patent cliff for Farxiga, makes it less likely that Astra’s drug will be a total game-changer. 

Pricey valuation

As I have written previously, Astra’s valuation seems very high to me. It currently trades at a forward P/E ratio of 25 and has a dividend yield of just under 3%. I believe that this is a stock priced for perfection, and this has historically not been a good situation to be in for investors. The data coming in from the Farxiga study has definitely lifted the ceiling on where this stock could go, but the market looks like it has already priced that potential in. For this reason I would still stay away from the stock.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »